BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

467 related articles for article (PubMed ID: 15200450)

  • 1. The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane.
    Williams JD; Topley N; Craig KJ; Mackenzie RK; Pischetsrieder M; Lage C; Passlick-Deetjen J;
    Kidney Int; 2004 Jul; 66(1):408-18. PubMed ID: 15200450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical biocompatibility of a neutral peritoneal dialysis solution with minimal glucose-degradation products--a 1-year randomized control trial.
    Szeto CC; Chow KM; Lam CW; Leung CB; Kwan BC; Chung KY; Law MC; Li PK
    Nephrol Dial Transplant; 2007 Feb; 22(2):552-9. PubMed ID: 17005526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bicarbonate/lactate-based peritoneal dialysis solution increases cancer antigen 125 and decreases hyaluronic acid levels.
    Jones S; Holmes CJ; Krediet RT; Mackenzie R; Faict D; Tranaeus A; Williams JD; Coles GA; Topley N;
    Kidney Int; 2001 Apr; 59(4):1529-38. PubMed ID: 11260417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biocompatibility and tolerability of a purely bicarbonate-buffered peritoneal dialysis solution.
    Weiss L; Stegmayr B; Malmsten G; Tejde M; Hadimeri H; Siegert CE; Ahlmén J; Larsson R; Ingman B; Simonsen O; van Hamersvelt HW; Johansson AC; Hylander B; Mayr M; Nilsson PH; Andersson PO; De los Ríos T
    Perit Dial Int; 2009; 29(6):647-55. PubMed ID: 19910566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term clinical effects of a peritoneal dialysis fluid with less glucose degradation products.
    Rippe B; Simonsen O; Heimbürger O; Christensson A; Haraldsson B; Stelin G; Weiss L; Nielsen FD; Bro S; Friedberg M; Wieslander A
    Kidney Int; 2001 Jan; 59(1):348-57. PubMed ID: 11135090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glucose degradation products in PD fluids: do they disappear from the peritoneal cavity and enter the systemic circulation?
    Zeier M; Schwenger V; Deppisch R; Haug U; Weigel K; Bahner U; Wanner C; Schneider H; Henle T; Ritz E
    Kidney Int; 2003 Jan; 63(1):298-305. PubMed ID: 12472796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of neutral pH and low-glucose degradation product-containing peritoneal dialysis fluid on systemic markers of inflammation and endothelial dysfunction: a randomized controlled 1-year follow-up study.
    Park SH; Do JY; Kim YH; Lee HY; Kim BS; Shin SK; Kim HC; Chang YK; Yang JO; Chung HC; Kim CD; Lee WK; Kim JY; Kim YL
    Nephrol Dial Transplant; 2012 Mar; 27(3):1191-9. PubMed ID: 21862454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of Conversion to a Bicarbonate/Lactate-Buffered, Neutral-pH, Low-GDP PD Regimen in Prevalent PD: A 2-Year Randomized Clinical Trial.
    Farhat K; Douma CE; Ferrantelli E; Ter Wee PM; Beelen RHJ; van Ittersum FJ
    Perit Dial Int; 2017; 37(3):273-282. PubMed ID: 28348100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The clinical usefulness of peritoneal dialysis fluids with neutral pH and low glucose degradation product concentration: an open randomized prospective trial.
    Choi HY; Kim DK; Lee TH; Moon SJ; Han SH; Lee JE; Kim BS; Park HC; Choi KH; Ha SK; Han DS; Lee HY
    Perit Dial Int; 2008; 28(2):174-82. PubMed ID: 18332454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biocompatible dialysis fluids for peritoneal dialysis.
    Cho Y; Johnson DW; Craig JC; Strippoli GF; Badve SV; Wiggins KJ
    Cochrane Database Syst Rev; 2014 Mar; (3):CD007554. PubMed ID: 24671928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biocompatible dialysis fluids for peritoneal dialysis.
    Htay H; Johnson DW; Wiggins KJ; Badve SV; Craig JC; Strippoli GF; Cho Y
    Cochrane Database Syst Rev; 2018 Oct; 10(10):CD007554. PubMed ID: 30362116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The influence of bicarbonate/lactate-buffered PD fluids on N{ε}-(carboxyethyl)lysine and N{ε}-(carboxymethyl)lysine in peritoneal effluent.
    Cnossen TT; Gladziwa U; van de Kerkhof JJ; Schalkwijk CG; Scheijen J; van Amersfoort J; Moret K; Beerenhout CH; Kooman JP
    Perit Dial Int; 2011; 31(2):189-93. PubMed ID: 20671103
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Benefits of biocompatible PD fluid for preservation of residual renal function in incident CAPD patients: a 1-year study.
    Kim S; Oh J; Kim S; Chung W; Ahn C; Kim SG; Oh KH
    Nephrol Dial Transplant; 2009 Sep; 24(9):2899-908. PubMed ID: 19258384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A combination of biocompatible peritoneal dialysis solutions and residual renal function, peritoneal transport, and inflammation markers: a randomized clinical trial.
    Lui SL; Yung S; Yim A; Wong KM; Tong KL; Wong KS; Li CS; Au TC; Lo WK; Ho YW; Ng F; Tang C; Chan TM
    Am J Kidney Dis; 2012 Dec; 60(6):966-75. PubMed ID: 22835900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BIOKID: randomized controlled trial comparing bicarbonate and lactate buffer in biocompatible peritoneal dialysis solutions in children [ISRCTN81137991].
    Nau B; Schmitt CP; Almeida M; Arbeiter K; Ardissino G; Bonzel KE; Edefonti A; Fischbach M; Haluany K; Misselwitz J; Kemper MJ; Rönnholm K; Wygoda S; Schaefer F;
    BMC Nephrol; 2004 Oct; 5():14. PubMed ID: 15485574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of balance Solution on the Peritoneal Membrane in Automated Peritoneal Dialysis.
    De Los Ríos T; Pérez-Martínez J; Portoles J; Lichodziejewska-Niemierko M; Rivera M; Nowicki M; Książek A; Tato AM; Bohnhorst C; Feriani M
    Perit Dial Int; 2016 9-10; 36(5):569-72. PubMed ID: 27659931
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A study of the clinical and biochemical profile of peritoneal dialysis fluid low in glucose degradation products.
    Lai KN; Lam MF; Leung JC; Chan LY; Lam CW; Chan IH; Chan HW; Li CS; Wong SS; Ho YW; Cheuk A; Tong MK; Tang SC
    Perit Dial Int; 2012; 32(3):280-91. PubMed ID: 22045098
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-GDP fluid (Gambrosol trio) attenuates decline of residual renal function in PD patients: a prospective randomized study.
    Haag-Weber M; Krämer R; Haake R; Islam MS; Prischl F; Haug U; Nabut JL; Deppisch R;
    Nephrol Dial Transplant; 2010 Jul; 25(7):2288-96. PubMed ID: 20197284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced systemic advanced glycation end products in children receiving peritoneal dialysis with low glucose degradation product content.
    Schmitt CP; von Heyl D; Rieger S; Arbeiter K; Bonzel KE; Fischbach M; Misselwitz J; Pieper AK; Schaefer F;
    Nephrol Dial Transplant; 2007 Jul; 22(7):2038-44. PubMed ID: 17420168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of peritoneal transport and membrane status in peritoneal dialysis: focus on incident fast transporters.
    Rodrigues AS; Martins M; Korevaar JC; Silva S; Oliveira JC; Cabrita A; Castro e Melo J; Krediet RT
    Am J Nephrol; 2007; 27(1):84-91. PubMed ID: 17284895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.